Ondansétron Accord (Ondansetron)

Ondansetron is employed across several therapeutic pathways to control nausea and vomiting.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiotherapy‑induced nausea and vomiting: helps maintain patient comfort during and after treatment.
• Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures.
• Pregnancy‑associated nausea (hyperemesis gravidarum): used when other measures are insufficient, under specialist supervision.
• Anticipatory nausea: lessens nausea that develops before chemotherapy cycles in patients with prior experience.

• Ondansetron selectively blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it interrupts the neural signalling cascade that initiates the vomiting reflex, thereby providing anti‑emetic protection during emetogenic stimuli.

Side‑effect profiles reflect the drug’s pharmacology and patient variability.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel slowing.
• Diarrhoea: transient loose stools.
• Fatigue: general tiredness.
• Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

• QT‑interval prolongation: may predispose to cardiac arrhythmias.
• Severe hypersensitivity: rash, itching, swelling or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Neuroleptic malignant‑like reactions: extremely uncommon but serious.

When prescribing Ondansétron Accord, clinicians should consider several safety aspects.

• Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte disturbances.
• Electrolyte balance: correct hypokalaemia or hypomagnesaemia before initiation.
• Concomitant serotonergic drugs: evaluate risk of serotonin syndrome.
• Pregnancy and lactation: use only if clearly indicated after risk‑benefit assessment.
• Renal or hepatic impairment: dose adjustment may be required based on clinical judgement.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Apomorphine: may cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic agents (e.g., quinidine, amiodarone): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely)

• Other serotonergic agents (e.g., SSRIs, tramadol): monitor for serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower ondansetron exposure.
• Diuretics causing electrolyte loss: watch for additive QT‑prolongation risk.